13F Holdings
中文EN

BCYC BICYCLE THERAPEUTICS PLC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1761612 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY194.7%
TTM net income YoY43.4%
TTM EPS YoY43.9%
Revenue 3-yr CAGR49.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-189.4%
Net margin-169.8%
FCF margin-211.9%
EBITDA margin-183.8%

Returns

ROE-25.2%
ROA-21.3%
ROIC (approx.)-4,542.9%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets10.9%
Debt / equity0.00x
Current ratio12.09x
Interest coverage-815.60x

Cash quality & payout

Operating cash flow / net income1.24x
Accruals ratio5.0%
Payout ratio—
Capex / revenue2.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$72.59M$35.27M$26.98M$14.46M$11.70M
R&D expense$240.28M$172.97M$156.50M$81.61M$44.88M
SG&A expense$79.37M$72.18M$60.43M$49.51M$32.44M
Operating income-$247.06M-$209.87M-$189.95M-$116.65M-$65.62M
Interest expense$206,000$1.73M$3.26M$3.34M$2.98M
Pretax income-$218.81M-$173.80M-$179.21M-$114.24M-$68.48M
Income tax$152,000-$4.76M$1.46M-$1.52M-$1.66M
Net income-$218.96M-$169.03M-$180.66M-$112.72M-$66.82M
EBITDA-$240.64M-$202.70M-$183.40M-$112.96M-$64.21M
EPS (basic)-3.16-2.90-5.08-3.80-2.67
EPS (diluted)-3.16-2.90-5.08-3.80-2.67
Dividends declared per share0.000.000.000.00—
Weighted avg. shares (diluted)69.28M58.21M35.59M29.66M25.06M
Balance sheet
Cash & equivalents$628.11M$880.07M$526.42M$339.15M$438.68M
Receivables$0$0$0$2.04M$1.00M
Current assets$682.88M$928.61M$561.87M$369.38M$458.56M
PP&E, net$6.02M$9.52M$14.52M$19.11M$3.12M
Total assets$717.60M$956.87M$595.34M$410.61M$479.79M
Current liabilities$56.98M$67.23M$69.54M$53.34M$36.24M
Long-term debt——$30.70M$30.32M$29.87M
Total debt——$30.70M$30.32M$29.87M
Total liabilities$107.62M$163.81M$224.41M$139.83M$133.54M
Shareholders' equity$609.98M$793.06M$370.93M$270.78M$346.25M
Net debt——-$495.73M-$308.84M-$408.81M
Shares outstanding69.37M69.06M42.43M29.87M29.58M
Cash flow statement
Operating cash flow-$249.68M-$164.72M-$60.63M-$86.11M-$14.79M
Capital expenditure$2.35M$1.24M$2.93M$18.99M$2.03M
Free cash flow-$252.03M-$165.96M-$63.56M-$105.10M-$16.82M
Investing cash flow-$2.35M-$1.24M-$2.93M-$18.99M-$2.03M
Financing cash flow-$131,000$519.75M$250.03M$6.69M$320.73M
Depreciation & amortization$6.42M$7.17M$6.55M$3.69M$1.41M
Stock-based compensation$39.46M$38.08M$32.48M$26.78M$12.08M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.